In vitro antibody affinity maturation has generally been achieved by display of mouse or human antibodies on the surface of microorganisms (phage, bacteria, and yeast). However, problems with protein folding, posttranslational modification, and codon usage still limit the number of improved antibodies that can be obtained. An ideal system would select and improve antibodies in a mammalian cell environment where they are naturally made. Here we show that human embryonic kidney 293T cells that are widely used for transient protein expression can be used for cell surface display of single-chain Fv antibodies for affinity maturation. In a proof-of-concept experiment, cells expressing a rare mutant antibody with higher affinity were enriched 240-fold by a single-pass cell sorting from a large excess of cells expressing WT antibody with a slightly lower affinity. Furthermore, we successfully obtained a highly enriched mutant with increased binding affinity for CD22 after a single selection of a combinatory library randomizing an intrinsic antibody hotspot. Important features are that one display selection cycle requires only 1 week, and transfection of cells in a single 100-mm dish produces 10 7 individual clones so that a repertoire of 10 9 is feasible under current experimental conditions.
antibody engineering ͉ B cell malignancy ͉ FACS ͉ human embryonic kidney cells ͉ receptors C reating high-affinity antibodies to important biomolecules for clinical use is an important and challenging task. Seventeen therapeutic mAbs have been approved by the Food and Drug Administration, and many more mAbs will be approved in the next few years (reviewed in ref. 1) . The levels of antibody affinity obtained from hybridomas are often not sufficient for effective clinical use in part because of the in vivo affinity ceiling (2, 3) ; therefore an improvement of antibody affinity is often required (4) . For the past 2 decades phage display was used for in vitro antibody affinity maturation (5) (6) (7) (8) (9) (10) , and more recently, bacterial (11) (12) (13) and yeast cell surface display systems have been developed (14) (15) (16) . A significant advantage of cell surface display over phage display is the use of quantitative flow cytometric sorting and analysis to identify high-affinity interactions and normalize for antibody protein expression. Cell-free systems like ribosome display are useful tools in antibody affinity maturation because of the large size of libraries (10 13 to 10 14 ) that can be produced and analyzed (17) (18) (19) . These techniques have all been successful, but problems with protein folding, posttranslational modification, and codon usage limit the number of improved antibodies that can be obtained (20) . Many potential therapeutic proteins are highly aggregation-prone upon heterologous expression in bacteria (21) . Moreover, serious translational problems can occur when proteins selected in bacteria, yeast, or cell-free systems are transferred into mammalian expression systems to produce therapeutic antibodies.
Mammalian cells such as Chinese hamster ovary cells are the dominant system used for the production of the majority of therapeutic antibodies in the pharmaceutical industry (22) . Therefore, mammalian cells should be used in antibody selection to avoid problems caused by selection in microorganisms. To use an animal cell environment for antibody selection and affinity maturation, a hypermutating chicken B lymphoma line (23) and a retrovirus display system (20) have been developed. Recently, a random peptide library fused to CCR5 and expressed on the mammalian cell surface has been reported (24) . The potential of this display system has been demonstrated for small peptides of 9 or 13 aa. A mammalian cell surface-displayed antibody system, which is robust and comparable to existing phage and yeast display technologies used in antibody engineering, has not yet been reported. Here, we show that human cells can be engineered for cell surface display of functional single-chain Fv (scFv) antibodies and is suitable for affinity maturation. For this purpose we have used the anti-CD22 scFv fused to the transmembrane domain of human platelet-derived growth factor receptor (PDGFR) displayed on human embryonic kidney (HEK) 293T cells. We find that the mammalian cell scaffold allows a 240-fold single-pass enrichment of a rare higher-affinity mutant from a large excess of only slightly lower-affinity WT antibody. Furthermore, we show that a mutant with an increased binding affinity for CD22 can be obtained after a single-pass selection of a combinatory library randomizing an intrinsic antibody hotspot.
Results
Expression and Surface Localization of scFv. We first determined whether HEK 293T cells, widely used for transient protein expression, could be engineered for cell surface display of functional antibody Fvs. Because of our interest in targeting CD22-expressing cancers, we chose the anti-CD22 scFv RFB4 fused to the transmembrane domain of PDGFR as the experimental system. The expression vector contains the cytomegalovirus promoter and the nucleotide sequence encoding the murine Ig chain signal peptide (METDTLLLWVLLL-WVPGSTGDJ) and the transmembrane domain (amino acids 514 -562) of PDGFR (25) . Fusion to the N-terminal portion of PDGFR has been used to anchor other proteins such as a virus hemagglutinin (26) , toll-like receptors (27) , and a chimeric human IgG-cat allergen fusion protein (28) .
We expressed WT anti-CD22 BL22 (RFB4) scFv or its high-affinity derivative, HA22 scFv, on HEK 293T human cells (Fig. 1A) . For comparisons, scFvs were also expressed in phage (10) or yeast display systems. Fig. 1B shows a structural model of the BL22 Fv. The protein contains a myc epitope tag at the carboxyl terminal of the scFv that is used to measure the expression level. A time-course experiment indicated that the expression level of transfected scFv-PDGFR is maximized 48-72 h after transfection (data not shown). Surface localization of the scFv-PDGFR fusion was verified by confocal fluorescence microscopy and flow cytometry. Cells labeled simultaneously with biotinylated CD22-Fc proteins and an anti-c-myc mAb were examined by laser scanning confocal microscopy ( Fig. 2) . Cells bearing the surface display vector expressing the scFv-PDGFR fusion protein were colabeled (yellow) by a mixture of the CD22-Fc (red) and the anti-c-myc antibody (green) (Fig. 2) . In contrast, control HEK 293T cells were not labeled by CD22-Fc or anti-c-myc mAb (data not shown).
FACS staining of the scFv-PDGFR fusion protein on the cell surface 48 h after transfection is shown in Fig. 3 . The scFvs were reacted with biotinylated CD22-Fc proteins to assess CD22-specific binding and simultaneously with an anti-c-myc mAb 9E10 to normalize expression levels of the scFv. Two-color flow cytometric analysis of the HEK 293T cells demonstrated both scFv expression (FITC for the level of 9E10 binding) and specific binding to the CD22 antigen [phycoerythrin (PE) level for CD22 binding]. The diagonal-like expression profile in Fig. 3B indicates that the transfected HEK 293T cells express various numbers of scFvs on the cell surface, each of which can bind to CD22. CD22 binding was not prevented by adding a CD30-Fc protein (data not shown), indicating that scFv binding to CD22 is specific. Likewise, when an isotype control mAb was used instead of 9E10, no antigen expression (FITC) was detected (data not shown), indicating that the FITC staining is caused by a specific interaction between the c-myc epitope tag and 9E10. These results demonstrate that mammalian HEK 293T cells can be engineered to display a functional antibody Fv at the cell surface. Moreover, antigen binding and Fv expression can be measured simultaneously and quantitatively, an important feature in obtaining Fvs with improved affinities.
The same anti-CD22 scFv was displayed on the surface of yeast ( Fig. 3 C and D) . We found 30-40% of yeast cells did not express scFv on their surface, resulting in two histogram peaks. The presence of nonexpressing population is consistent with published yeast display experiments (14, 16) .
Fine Discrimination by Mammalian Cell Surface Display. To determine whether this system could discriminate between Fvs with different affinities, a step essential in affinity maturation, we chose the BL22 scFv, now in clinical use, and a 2-fold higheraffinity mutant (HA22) and displayed them on the surface of HEK 293T cells. The scFv BL22-displaying cells were mixed with scFv HA22-displaying cells at a 400:1 ratio. This ratio was chosen because in a typical hotspot-based selection, DNA encoding two amino acids is mutagenized and the library has (20 ϫ 20) 400 mutants with different amino acids. The cell mixture was incubated in 1 nM CD22-Fc and 9E10 at 25°C for 1 h. Cells were then fluorescently labeled and sorted. The flow cytometric sorting instrument used here can sort 10,000-20,000 cells per s. Sorting of 10 7 cells (one 100-mm dish) takes Ϸ10 min. The sort window was set to obtain the top 0.1% (Ϸ10 4 ) high CD22 binders (29) (Fig. 4) . The window covers an area with a range of different scFv expression levels measured by the anti-c-myc antibody so that mutant scFvs with a high affinity to CD22 can be selected regardless of their expression levels. Plasmid DNA was directly extracted from collected HEK 293T cells and transformed into Escherichia coli for isolation and sequencing of inserts. Interestingly, 6 of 10 clones contained the scFv HA22 sequence, whereas 4 were scFv BL22 clones. Therefore, the single-pass enrichment of scFv HA22-displaying cells was 240-fold, although the difference in the affinity of the HA22 and the original BL22 (RFB4) is only Ϸ2-fold. 
Construction of a HEK 293T Cell Surface Display Library for in Vitro
Antibody Affinity Maturation. Finally, we asked whether this system could be suitable for isolating a high binder that could be used to make a more active immunotoxin or for other targeted therapies from a combinatory library. We constructed a HEK 293T cell surface-displayed combinatory library randomizing an intrinsic antibody hotspot. There are six complementary determining regions (CDRs), three on antibody heavy chain and three on light chain. CDRs are involved in antigen binding. Previous work has shown that a small number of DNA residues in CDRs called hotspots (30) (31) (32) (33) can be used to increase antibody affinity (9, 10, 34, 35) . Here we used the same strategy to select a hotspot (Gly-91-Asn-92) in light-chain CDR3 of HA22 to construct an anti-CD22 scFv library.
The scFv library was transduced into E. coli cells by electroporation. The library complexity of RFB4LibVL30͞31 consisted of Ͼ1 ϫ 10 4 independent clones. Because a library of 1,024 (32 ϫ 32) independent clones is needed to randomly mutate the hotspot sequence (GGTAAT) to NNSNNS, the size of the current library is 10-fold larger than the one required. Sequence analysis of 10 independent clones demonstrated that the targeted hotspot residues were successfully randomized (data not shown). The library was then transfected into HEK 293T cells with Lipofectamine and the Fv expressed on the cell surface was fused to the PDGFR transmembrane domain (Fig. 1) .
Isolation of Mutant scFv With a Higher Affinity from a HEK 293T Cell
Surface Display Library. One transfection in a 100-mm Petri dish can produce Ϸ10 7 transfected HEK 293T cells. Because the required library size is only Ϸ1,000, the high transfection rate of one dish of HEK 293T cells produced a library with Ͼ10 4 copies of each clone. Forty-eight hours after transfection, the mutant Binding Affinity Analysis of the New Mutant. Four individual clones each with the same PT mutation were analyzed for binding affinity. HEK 293T cell surface-displayed scFv HA22, and the PT mutants were incubated with 2 nM biotinylated CD22-Fc, a concentration equivalent to the dissociation constant for CD22 of the starting scFv HA22 (10) . The expression levels of the HA22 scFv and mutant scFvs were similar as measured by the mean fluorescence intensity (MFI) of FITC. In contrast, the CD22 binding measured as MFI of PE was remarkably higher in all of the PT mutants (Fig. 5A) . The MFI of cells was converted to the number of molecules of fluorochrome per cell by using calibration beads. The transfected HEK 293T cells have Ϸ15,000 scFv molecules on the surface.
The CD22 binding affinity of each HEK 293T cell surfacedisplayed single-chain antibody was determined from equilibrium binding titration curves (29) obtained by incubating Fvexpressing cells in various concentrations of biotinylated CD22-Fc (see Materials and Methods). Fig. 5B shows results of two independent titrations of cell surface-displayed BL22, HA22, and PT. The equilibrium dissociation constant, K D , was fit by nonlinear least squares. The affinity of HEK 293T cell surface-displayed PT mutant for CD22 (K D ϭ 1.2 nM) is Ϸ2-fold higher than that for HA22 (K D ϭ 2.5 nM) and Ϸ5-fold higher than that for WT BL22 (K D ϭ 5.8 nM). The HA22 and BL22 affinity values are consistent with those previously measured by flow cytometric analysis of Daudi cells using immunotoxin proteins (10) .
Discussion
Here, we show that mammalian (HEK 293T) cells can be engineered to display a functional antibody Fv at the cell surface and be used to facilitate antibody affinity maturation. The results demonstrate that functional scFvs can be displayed on the cell surface in a manner accessible for protein antigen recognition. Furthermore, the system is amenable to construction of a combinatorial library and high-throughput screening for affinity maturation by flow cytometry. We report that a mammalian cell surface display system can be used for in vitro antibody affinity maturation and serves as a proof of concept for an approach to antibody engineering. The scFv selected can be easily converted to whole IgG antibodies or immunotoxins, Fv-toxin chimeric proteins, for clinical use. The application of this display system in affinity maturation for antibodies, T cell receptors (36) , and other biologically important molecules should be a significant alternative to existing technologies for affinity-based selections such as phage display, bacterial surface display, and yeast cell surface display.
Important features of this system are (i) that it is compatible with other mammalian expression systems and (ii) that it is a rapid, robust, and relatively simple procedure. Starting with a Fv expression library it requires only 7 days to identify the DNA sequence of clones enriched by the selection and the DNA is ready for the next round of selection (Table 1) . Microorganisms currently used in antibody engineering can have problems with protein folding, posttranslational modification, and codon usage (20) . Serious problems often occur when antibody mutants selected in phage display are transferred into mammalian expression systems, which are widely used in the pharmaceutical industry to produce active therapeutic antibodies. Therefore, a mammalian expression system that can be used in antibody selection and affinity maturation would be very useful.
We have demonstrated the feasibility of this approach by fusing the single-chain antibody sequence at the amino terminus of the PDGFR transmembrane domain downstream of the signal sequence of the Ig chain. Other methods for expression on the cell surface could involve fusion to any natural receptor of choice, a glycosylphosphatidylinositol-anchored protein (24) , or an artificial construct.
One important advantage of cell-based display over phage display is that we can monitor the expression level of each Fv on each cell by FACS and use the expression level to normalize the antibody-binding signal based on the number of Fvs on the cell surface. Expression systems typically exhibit a wide range of variation in the amount of protein displayed, and mutations in Fvs often produce mutant proteins with altered expression levels. These variations should not interfere with selections in a cell surface display system, making it possible to isolate better binders even with a slight difference in affinity. In a proof-ofconcept experiment, HEK 293T cells expressing a rare mutant antibody were enriched 240-fold by a single-pass cell sorting from a large excess of cells expressing WT antibodies with slightly lower affinity. The sort window was set to obtain the top 0.1% of cells with high CD22 binding normalized for Fv expression (Fig. 4) . Under similar conditions, a single-pass enrichment of bacterial cells and yeast cells was 300-and 125-fold, respectively (13, 29) . One obvious challenge when using cell-based systems rather than in vitro-based ribosomal display is the limited library size that can be obtained because of restrictions in the transformation step. Phage display has the largest library size (10 9 ) (19) . The antibody library size in yeast is typically 10 6 (37, 38) . Libraries of this size have been successfully used for many purposes. Such libraries may include hypothesis-driven (as described here) or semirandom mutagenesis for affinity maturation, human recombinant antibody libraries from patients, and hyperimmunized mouse spleen-derived recombinant libraries. In the present study, transient transfection of HEK 293T cells in a 100-mm dish produced 10 7 individual clones. The same procedure can easily be expanded to 100 dishes in 1 day. The high-speed flow cytometric sorting machine (FACSVantage SE, BD Biosciences, San Jose, CA) has the capacity to screen 10 9 cells in 1 day. Therefore, the library size of the mammalian display described here is comparable to phage and yeast display methods that are commonly used.
The high-affinity mutant described here may be useful in the treatment of patients with B cell malignancies. CD22 is a B cell antigen expressed in B cell lymphomas and leukemias and not expressed on stem cells or early in B cell development (39) (40) (41) . We have shown that more than half of patients with drugresistant hairy cell leukemia can be brought into complete remission (42) by using the BL22 immunotoxin derived from anti-CD22 antibody (reviewed in ref. 43 ). The high-affinity mutant described here may expand the use of BL22 mutants in the treatment of patients with chronic lymphocytic leukemia, in which the cells have relatively small amounts of CD22 (44, 45) .
Materials and Methods
Construction of Mammalian Cell Surface Display Library. Table 1 outlines the experimental procedure for making an Fv library for affinity maturation by mammalian cell surface display. We displayed mutant library of anti-CD22 scFv on HEK 293T cells. The surface display library was constructed by randomly mutagenizing a hotspot (Gly-91-Asn-92) in light-chain CDR3 of anti-CD22 HA22 scFv. HA22 scFv already contains mutations in the heavy-chain CDR3 hotspot of an anti-CD22 mAb RFB4 (35) . The mutagenesis of HA22 scFv was performed as described (10) . Degenerate oligomers with NNS were used (N randomizing with all four nucleotides, S introducing C or G) in two-step overlap extension PCR: DisSfiIF, 5Ј-GGGGCCCAGCCGGC-CATGGAAGTGCAGCTGGTG-3Ј; DisSacIIR, 5Ј-CTGC-CGCGGAGCTTTGATTTCCAG-3Ј; RFB4VL91͞92F, 5Ј-T T T TGCCA ACAGNNSNNSACGCT TCCGTGG-3Ј; and RFB4VLl91͞92R, 5Ј-CCACGGAAGCGTSNNSNNCTGTT-GGCAAAA-3Ј. Phagemid pCANTAB5E-scFv HA22 (clone G3) was used as a template. The PCR product was subcloned into SfiI and SacII sites downstream of the Ig chain leader sequence of the pDisplay vector (Invitrogen). The vector encodes a myc epitope tag and a PDGFR transmembrane domain downstream of the scFv. The ligation mix was used to transform electroporation-competent E. coli cells. Each transformation produced a cell surface display library containing Ϸ1 ϫ 10 6 independent clones. The plasmid library, pDisplay-RFB4VL91͞92, contains a mutation targeting G91-N92 residues in light-chain CDR3 of the HA22 scFv. We also made plasmids pDisplay-BL22 (pMH112) and pDisplay-HA22 (pMH113) containing scFv BL22 (RFB4) and HA22, respectively, as controls.
Transfection. The scFv protein was expressed as a fusion to PDGFR transmembrane domain in transfected HEK 293T cells (10) . Lipofectamine (Invitrogen) was used for transfections. Five micrograms of plasmid DNA was used for transfection in a 100-mm Petri dish containing 10 7 HEK 293T cells per dish.
Confocal Fluorescence Microscopy. HEK 293T cells transfected with pMH113 were grown on cover slips. After 48 h, cells were washed with PBS and fixed in 1 ml of 4% formaldehyde in PBS for 10 min at 25°C. Cells were blocked with 5% BSA in PBS for 30 min at 25°C and then incubated with 1 g͞ml of biotinylated CD22-Fc or CD30-Fc proteins and 20 g͞ml of mAb 9E10 (anti-c-myc) or IgG1 isotype control (Sigma) in PBS containing 5% BSA and 0.1% sodium azide. After incubation for 90 min at 25°C, cover slips were washed, incubated with Alexa Fluor-488-labeled goat anti-mouse IgG (1:500; Molecular Probes) and streptavidin-Alexa Fluor-594 conjugate (1:500; Molecular Probes) for 60 min at 25°C, and washed. To visualize the nucleus, cells were stained with DAPI (Molecular Probes) for 5 min at 25°C. Slides were analyzed in a Zeiss LSM 510 confocal microscope. In some experiments (Fig. 5A ), the MFI of cells was converted to the molecular number of fluorochrome (FITC, PE) on cells using Quantum FITC MESF (Bangs Laboratories, Carmel, IN) or QuantiBrite PE (BD Biosciences) calibration beads. 7 HEK 293T cells were incubated with 0.2 nM biotinylated CD22-Fc proteins and 20 g͞ml of 9E10 mAb in PBS buffer at 25°C for 1 h. Finally, the cells were rinsed with ice-cold PBS buffer and labeled with FITC-antimouse IgG and streptavidin-PE conjugate as described above. Samples were sorted on a FACSVantage SE (BD Biosciences) with a sort window as shown in Fig.  4 . During a single-pass sorting, 1 ϫ 10 7 HEK 293T cells were examined and the window was set to collect 0.1% of the population.
Yeast Display. For a comparison between the mammalian cell surface display and yeast display, we expressed the HA22 scFv on yeast. The pYD1 vector (Invitrogen) and Saccharomyces cerevisiae strain EBY100 (14) was used for yeast cell surface display of anti-CD22 scFv HA22. The HA22 scFv was fused to the carboxyl terminus of Aga2p, and the fusion tethered to the yeast cell surface by disulfide bonding to the anchoring subunit Aga1p (Fig. 1) . Each scFv contains a carboxyl-terminal V5 epitope tag. The pMH111 plasmid contains the HA22 scFv insert at the EcoRI and XhoI sites. Yeast cells were transformed with pMH111 by using the S.c. EasyComp transformation kit (Invitrogen), and Trpϩ transformants were selected. Yeast cells containing scFv surface display plasmids were grown in minimal SD-CAA medium (20 (14) to induce scFv display. Induction was carried out at 20°C for 48 h.
In a typical protocol for f low cytometric analysis of yeast, cells were incubated on ice with 0.1-1 g͞ml of biotinylated CD22-Fc and mAb anti-V5 (10 g͞ml; Sigma) for 30 min, followed by anti-mouse FITC conjugate (1:200) and streptavidin-PE conjugate (1:200) for 1 h. FITC and PE f luorescence intensities were quantified with a FACalibur f low cytometer (Becton Dickinson).
Preparation and Purification of CD22. CD22-Fc fusion proteins were prepared as described (10) . Biotinylation of CD22-Fc was performed according to the manufacturer's instruction (Pierce).
Determination of Affinity Constants (KD).
Antibody affinity measurements were performed with flow cytometry following protocols as described (16, 29) . Equilibrium constants and Scatchard plots were determined by using the Marquardt-Levenberg algorithm for nonlinear regression with PRISM software (version 3.0.2; GraphPad, San Diego).
Rescue of scFv Sequence. Plasmid DNA was isolated by using the QIAprep Spin Miniprep Kit following the manufacturer's instruction (Qiagen, Valencia, CA) from HEK 293T cells sorted on a FACSVantage SE (BD Biosciences). As few as 100 cells were enough for plasmid isolation. The plasmid DNA was transformed into TOP10F-competent E. coli (Invitrogen). Individual clones were used for sequencing and retransfection of HEK 293T cells. Alternatively, the plasmid DNAs recovered from HEK 293T cells were used as templates for a PCR using the Tgo DNA polymerase with 3Ј-5Ј exonuclease proofreading activity (Roche Diagnostics).
Sequencing Analysis and Structural Modeling. The scFv fragments isolated from HEK 293T cell surface library were sequenced with primers DisSfiIF and DisSacIIR (National Cancer Institute DNA Sequencing Core Facility, Bethesda).
Both the heavy-and light-chains variable region sequences were numbered following the Kabat rule (46) . Antibody Fv sequence analysis and structural modeling were performed as described (10) .
